Metavista3D and BrainBit: Revolutionizing Clinical Research with Advanced Display Technology

Metavista3D Inc. (TSXV: DDD) (FSE: E3T) and BrainBit Inc. have joined forces in a groundbreaking collaboration aimed at pushing the boundaries of clinical research and trials. The two companies have signed a 36-month Memorandum of Understanding (MOU) to integrate Metavista3D's cutting-edge pseudo-holographic 3D display technologies into BrainBit's advanced medical equipment. This innovative partnership is expected to redefine spatial reality experiences in clinical environments while eliminating the need for stereotypical 3D glasses.

Metavista3D, a pioneering force in pseudo-holographic display technologies, is at the forefront of developing AI-driven, pseudo-holographic display technologies designed to transform how we interact with spatial content. With over 20 patents and a commitment to innovation, Metavista3D is shaping the future of immersive, glasses-free 3D experiences. BrainBit, a high-technology hardware company founded in 2015, specializes in creating high-quality EEG, EMG, and Neurofeedback solutions for various companies worldwide. The collaboration between these two innovative companies is set to revolutionize the healthcare industry by enhancing healthcare outcomes and paving the way for novel applications in both medical and consumer healthcare sectors.

The integration of Metavista3D's pseudo-holographic 3D display technologies with BrainBit's advanced medical equipment is anticipated to deliver a unique visual experience, potentially transforming the way neurological and physiological data is interpreted in medical settings. By providing a glasses-free, immersive 3D experience, the technology caters to a broader range of users, including those with visual impairments or discomfort with traditional headgear. This collaboration not only highlights Metavista3D's commitment to technological advancement but also its vision of integrating state-of-the-art solutions into everyday health practices.

Together, Metavista3D and BrainBit will embark on a series of clinical studies and trials, seeking to enhance the effectiveness of BrainBit's wireless EEG, EMG, and ECG technologies. The combination of talents and resources from both parties anticipates groundbreaking outcomes that will significantly impact the healthcare industry. This collaboration not only highlights Metavista3D's commitment to technological advancement but also its vision of integrating state-of-the-art solutions into everyday health practices. Through this alliance, a new era of visual and data accuracy in medical diagnostics is within reach, promising substantial benefits for practitioners and patients alike.



In conclusion, the collaboration between Metavista3D and BrainBit is poised to revolutionize the healthcare industry by leveraging advanced display technologies to enhance clinical research and trials. By integrating Metavista3D's pseudo-holographic 3D display technologies with BrainBit's medical equipment, the two companies aim to deliver a unique visual experience that transforms the way neurological and physiological data is interpreted in medical settings. This innovative partnership is set to pave the way for novel applications in both medical and consumer healthcare sectors, ultimately leading to improved patient outcomes and enhanced healthcare practices.